HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Investors in Y-mAbs Therapeutics (YMAB) With Significant Losses to Contact the Firm’s Attorneys, Firm Investigating Possible Securities Law Violations
SAN FRANCISCO, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) investors who suffered significant losses to submit your losses now .
- SAN FRANCISCO, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) investors who suffered significant losses to submit your losses now .
- The briefing documents detail the FDAs efforts to facilitate Y-mAbs clinical development of I-omburtamab and pertinent drug development and regulatory history.
- If you invested in Y-mAbs and have significant losses, or have knowledge that may assist the firms investigation, click here to discuss your legal rights with Hagens Berman .
- Hagens Berman is a global plaintiffs rights complex litigation law firm focusing on corporate accountability through class-action law.